This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Active Biotech To Present At The Jefferies 2013 Global Healthcare Conference

Stocks in this article: ACTI

LUND, Sweden, Nov. 14, 2013 (GLOBE NEWSWIRE) --

Active Biotech (NASDAQ OMX NORDIC: ACTI) is
scheduled to present at the Jefferies Global Healthcare Conference held November
20-21, 2013 in London, UK. During the presentation, an update regarding Active
Biotech's development programs will be provided.

The presentation will include the laquinimod project, a novel oral
immunomodulatory drug primarily for the treatment of multiple sclerosis,
licensed to Teva Pharmaceutical, the Phase III prostate cancer project
tasquinimod in co-development with Ipsen, as well as ANYARA, Active Biotech's
novel concept for tumor therapy of primarily renal cell cancer. Also, the
project with paquinimod (57-57) and the pre-clinical ISI project will be
presented.

The audio and slide presentation will be webcasted live and can be accessed via
the Active Biotech web site. To access the live and replay presentations please
go to - www.activebiotech.com.

The presentation will take place on November 20, at 08:00 a.m. GMT (Greenwich
Mean Time) / 09:00 am Central European Time.

For further information, please contact:
Hans Kolam, CFO
Phone: +46 (0)46 19 20 44
E-mail: hans.kolam@activebiotech.com



Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. In pivotal phase is
laquinimod, an orally administered small molecule with unique immunomodulatory
properties for the treatment of multiple sclerosis. Also tasquinimod for the
treatment of prostate cancer, with a unique mode of action, is in pivotal phase.
In addition, laquinimod has concluded Phase II development for Crohn's and
Lupus. The company has two additional projects in clinical development, ANYARA
primarily for the treatment of renal cell cancer and the orally administered
compound paquinimod (57-57) for systemic sclerosis. Please visit
www.activebiotech.com for more information.

Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00

Active Biotech is obligated to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This information
was provided to the media for publication 8:30 a.m. CET on November 14, 2013.


Active Biotech to Present at the Jefferies 2013 Global Healthcare Conf: http://hugin.info/1002/R/1742843/586064.pdf

[HUG#1742843]

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs